206 related articles for article (PubMed ID: 31740809)
1. RIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockade.
Ruzicka M; Koenig LM; Formisano S; Boehmer DFR; Vick B; Heuer EM; Meinl H; Kocheise L; Zeitlhöfler M; Ahlfeld J; Kobold S; Endres S; Subklewe M; Duewell P; Schnurr M; Jeremias I; Lichtenegger FS; Rothenfusser S
Leukemia; 2020 Apr; 34(4):1017-1026. PubMed ID: 31740809
[TBL] [Abstract][Full Text] [Related]
2. Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia.
Shen W; Patnaik MM; Ruiz A; Russell SJ; Peng KW
Blood; 2016 Mar; 127(11):1449-58. PubMed ID: 26712908
[TBL] [Abstract][Full Text] [Related]
3. RIG-I activating immunostimulatory RNA boosts the efficacy of anticancer vaccines and synergizes with immune checkpoint blockade.
Heidegger S; Kreppel D; Bscheider M; Stritzke F; Nedelko T; Wintges A; Bek S; Fischer JC; Graalmann T; Kalinke U; Bassermann F; Haas T; Poeck H
EBioMedicine; 2019 Mar; 41():146-155. PubMed ID: 30852164
[TBL] [Abstract][Full Text] [Related]
4. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia.
Zhou Q; Munger ME; Veenstra RG; Weigel BJ; Hirashima M; Munn DH; Murphy WJ; Azuma M; Anderson AC; Kuchroo VK; Blazar BR
Blood; 2011 Apr; 117(17):4501-10. PubMed ID: 21385853
[TBL] [Abstract][Full Text] [Related]
5. MAVS-dependent IRF3/7 bypass of interferon β-induction restricts the response to measles infection in CD150Tg mouse bone marrow-derived dendritic cells.
Takaki H; Honda K; Atarashi K; Kobayashi F; Ebihara T; Oshiumi H; Matsumoto M; Shingai M; Seya T
Mol Immunol; 2014 Feb; 57(2):100-10. PubMed ID: 24096085
[TBL] [Abstract][Full Text] [Related]
6. CD4
Kristensen LK; Fröhlich C; Christensen C; Melander MC; Poulsen TT; Galler GR; Lantto J; Horak ID; Kragh M; Nielsen CH; Kjaer A
Theranostics; 2019; 9(26):8221-8238. PubMed ID: 31754392
[TBL] [Abstract][Full Text] [Related]
7. Myeloid maturation potentiates STAT3-mediated atypical IFN-γ signaling and upregulation of PD-1 ligands in AML and MDS.
Yoyen-Ermis D; Tunali G; Tavukcuoglu E; Horzum U; Ozkazanc D; Sutlu T; Buyukasik Y; Esendagli G
Sci Rep; 2019 Aug; 9(1):11697. PubMed ID: 31406210
[TBL] [Abstract][Full Text] [Related]
8. Pyruvate Carboxylase Activates the RIG-I-like Receptor-Mediated Antiviral Immune Response by Targeting the MAVS signalosome.
Cao Z; Zhou Y; Zhu S; Feng J; Chen X; Liu S; Peng N; Yang X; Xu G; Zhu Y
Sci Rep; 2016 Feb; 6():22002. PubMed ID: 26906558
[TBL] [Abstract][Full Text] [Related]
9. Enhanced Anti-Leukemic Effects through Induction of Immunomodulating Microenvironment by Blocking CXCR4 and PD-L1 in an AML Mouse Model.
Hwang HS; Han AR; Lee JY; Park GS; Min WS; Kim HJ
Immunol Invest; 2019 Jan; 48(1):96-105. PubMed ID: 30204524
[TBL] [Abstract][Full Text] [Related]
10. RIG-I Mediates an Antiviral Response to Crimean-Congo Hemorrhagic Fever Virus.
Spengler JR; Patel JR; Chakrabarti AK; Zivcec M; García-Sastre A; Spiropoulou CF; Bergeron É
J Virol; 2015 Oct; 89(20):10219-29. PubMed ID: 26223644
[TBL] [Abstract][Full Text] [Related]
11. Monocyte chemoattractant protein 1 (MCP-1/CCL2) contributes to thymus atrophy in acute myeloid leukemia.
Driss V; Quesnel B; Brinster C
Eur J Immunol; 2015 Feb; 45(2):396-406. PubMed ID: 25382729
[TBL] [Abstract][Full Text] [Related]
12. TDP-43 prevents endogenous RNAs from triggering a lethal RIG-I-dependent interferon response.
Dunker W; Ye X; Zhao Y; Liu L; Richardson A; Karijolich J
Cell Rep; 2021 Apr; 35(2):108976. PubMed ID: 33852834
[TBL] [Abstract][Full Text] [Related]
13. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.
Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M
Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605
[TBL] [Abstract][Full Text] [Related]
14. Expression patterns of immune checkpoints in acute myeloid leukemia.
Chen C; Liang C; Wang S; Chio CL; Zhang Y; Zeng C; Chen S; Wang C; Li Y
J Hematol Oncol; 2020 Apr; 13(1):28. PubMed ID: 32245463
[TBL] [Abstract][Full Text] [Related]
15. PD-1 blockade potentially enhances adoptive cytotoxic T cell potency in a human acute myeloid leukaemia animal model.
Deng R; Fan FY; Yi H; Liu F; He GC; Sun HP; Su Y
Hematology; 2018 Dec; 23(10):740-746. PubMed ID: 29962321
[TBL] [Abstract][Full Text] [Related]
16. Vaccine immunotherapy with ARNAX induces tumor-specific memory T cells and durable anti-tumor immunity in mouse models.
Takeda Y; Yoshida S; Takashima K; Ishii-Mugikura N; Shime H; Seya T; Matsumoto M
Cancer Sci; 2018 Jul; 109(7):2119-2129. PubMed ID: 29791768
[TBL] [Abstract][Full Text] [Related]
17. Delivery of 5'-triphosphate RNA with endosomolytic nanoparticles potently activates RIG-I to improve cancer immunotherapy.
Jacobson ME; Wang-Bishop L; Becker KW; Wilson JT
Biomater Sci; 2019 Jan; 7(2):547-559. PubMed ID: 30379158
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic efficacy of bifunctional siRNA combining TGF-β1 silencing with RIG-I activation in pancreatic cancer.
Ellermeier J; Wei J; Duewell P; Hoves S; Stieg MR; Adunka T; Noerenberg D; Anders HJ; Mayr D; Poeck H; Hartmann G; Endres S; Schnurr M
Cancer Res; 2013 Mar; 73(6):1709-20. PubMed ID: 23338611
[TBL] [Abstract][Full Text] [Related]
19. Essential role of B7-H1 in double-stranded RNA-induced augmentation of an asthma phenotype in mice.
Matsumoto K; Kan-O K; Eguchi-Tsuda M; Fukuyama S; Asai Y; Matsumoto T; Moriwaki A; Matsunaga Y; Tsutsui H; Kawai T; Takeuchi O; Akira S; Yagita H; Azuma M; Nakanishi Y; Inoue H
Am J Respir Cell Mol Biol; 2011 Jul; 45(1):31-9. PubMed ID: 20802088
[TBL] [Abstract][Full Text] [Related]
20. Combination immunotherapy with interleukin-2 surface-modified tumor cell vaccine and programmed death receptor-1 blockade against renal cell carcinoma.
Zhang X; Shi X; Li J; Hu Z; Gao J; Wu S; Long Z
Cancer Sci; 2019 Jan; 110(1):31-39. PubMed ID: 30343514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
